Cas:146395-14-4 THP-PEG5-OH manufacturer & supplier

Chemical Name:THP-PEG5-OH

CAS.NO:146395-14-4

Synonyms:3,6,9,12-Tetraoxatetradecan-1-ol, 14-[(tetrahydro-2H-pyran-2-yl)oxy]-;14-(Tetrahydro-2H-pyran-2-yloxy)-3,6,9,12-tetraoxatetradecan-1-ol;MFCD26793753

Molecular Formula:C₁₅H₃₀O₇

Molecular Weight:322.395

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:432.5±45.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.469

PSA:

Exact Mass:322.199158

LogP:-1.82

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,6,9,12-Tetraoxatetradecan-1-ol, 14-[(tetrahydro-2H-pyran-2-yl)oxy]- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD26793753 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,14-(Tetrahydro-2H-pyran-2-yloxy)-3,6,9,12-tetraoxatetradecan-1-ol Use and application,3,6,9,12-Tetraoxatetradecan-1-ol, 14-[(tetrahydro-2H-pyran-2-yl)oxy]- technical grade,usp/ep/jp grade.

Related News: After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API. THP-PEG5-OH manufacturer The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. THP-PEG5-OH supplier After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API. THP-PEG5-OH vendor Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. THP-PEG5-OH factory But several border points remain open, and many medical workers fear that Hong Kong��s well-regarded health care system will be overwhelmed.